The London-listed group has added Peter Presland, Malcolm Glaister and Zakaria Aziz to its board as non-executive directors. Presland will be WideCells’ new chairman after the company confirmed Graham Hine has retired from the role.
The three new additions will all “bring a wealth of corporate experience”, WideCells said in Thursday’s statement.
Alongside the new board additions, WideCells has also created a Scientific Advisory Committee which will identify and advise the board on new developments within the stem cell sector.
The committee, which will be chaired by professor Tristan Mckay, will also help manage all research work for the group.
‘A new period of growth’
“With three divisions now operational and starting to generate revenues, we are about to embark on a new period of growth and development as we look to build our operational reach on an international scale, increase our client base, and ultimately transform the value profile of our company,” said chief executive João Andrade.
“We have welcomed three new board members, who bring a wealth of corporate knowledge and experience in the insurance, medical and financial industries, which will be invaluable to us as we target new markets and seek new commercial agreements to facilitate the roll-out of our stem cell services.
“To support this new board, and in line with our commitment to maintaining operational excellence and being at the fore of our field, we have also created a new Scientific Advisory Committee, which brings together some of the best brains in stem cell technology and regenerative medicine.
“The committee's unrivalled knowledge and prestigious network of contacts will I believe provide us with a number of exciting growth opportunities.”
WideCells also said it had appointed WG Partners as its joint broker as it looks to raise its institutional profile.